Is Bal Pharma a Good Buy After Its Q1 FY27 Results?

The Bal Pharma share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bal Pharma is a manufacturer of pharmaceutical formulations and active pharmaceutical ingredients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 89 crore, up 33.7% year on year, while profit after tax came in at Rs 1.14 crore, up 442.9% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bal Pharma share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Bal Pharma share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Bal Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 89 crore	Rs 67 crore	33.7%
EBITDA	Rs 8.38 crore	Rs 6.78 crore	23.6%
Operating Margin	9.5%	10.3%	NA
Profit Before Tax	Rs 1.14 crore	Rs 0.21 crore	442.9%
Net Profit / (Loss)	Rs 1.14 crore	Rs 0.21 crore	442.9%

Bal Pharma Q1 FY27 Performance Analysis

Check Bal Pharma Fundamentals on Univest Screener

Revenue growth of 33.7% for the quarter came from steady demand across the company's core business, keeping the topline trend intact for the pharmaceutical formulations and API manufacturing sector.

The bigger story is on profitability. PAT grew 443% to Rs 1.14 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. Worth flagging: the year-ago quarter's profit base of Rs 0.21 crore was unusually low, so the percentage growth looks more dramatic than the underlying trend. This is the kind of quarter that supports the premium the Bal Pharma share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.

On a sequential basis, revenue moved up 6.2% sequentially from Rs 84 crore in the March 2026 quarter and net profit moved down 68.3% sequentially from Rs 3.60 crore in the prior quarter, giving a fuller picture of the trend behind the Bal Pharma share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Bal Pharma's revenue grew 33.7% year on year this quarter, taking the quarterly base to Rs 89 crore in a pharmaceutical formulations and API manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Bal Pharma share price.

Margin Movement

EBITDA rose 23.6% to Rs 8.38 crore, and operating margin moved to 9.5% from 10.3% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

Bal Pharma's debt-to-equity ratio stands at 1.94, a level worth monitoring given the quarter's margin trend.

Valuation Context

The stock trades at a PE of 20.9x, below the industry average of 38.0x, which is worth factoring into any read of whether the Bal Pharma share price is expensive or reasonably priced.

Dividend Details

No interim dividend was declared alongside Bal Pharma's Q1 FY27 results. The stock currently carries a trailing dividend yield of 1.26%, based on dividends paid over the last year. Investors tracking the Bal Pharma share price for income should watch the company's announcements around its next annual results for any dividend decision.

Bal Pharma Share Price Outlook for FY27

The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Bal Pharma can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter's momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.

For the Bal Pharma share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter's pace, since any slowdown would put pressure on a stock priced for continued strength.

Bal Pharma Stock Performance

Download the Univest iOS App or Univest Android App to track Bal Pharma's live share price and get daily stock updates.

The Bal Pharma share price was trading around Rs 114 as results season played out in late August 2026, roughly 0.0% below its 52-week high of Rs 114 and well above its 52-week low of Rs 60.

The Bal Pharma share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 7.64% and a book value of around Rs 52 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Leverage Risk

A debt-to-equity ratio of 1.94 means the company's earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer.

Sector and Demand Risk

As a pharmaceutical formulations and API manufacturing business, Bal Pharma's results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Bal Pharma share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Bal Pharma's Q1 FY27 results were genuinely strong, with revenue at Rs 89 crore and PAT up 443% to Rs 1.14 crore. That said, at a PE of 20.9x, the Bal Pharma share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Bal Pharma is a good buy should weigh the strong quarter against the valuation before adding at current levels.

Frequently Asked Questions on Bal Pharma Q1 FY27 Results

What were Bal Pharma's Q1 FY27 results?

Ans. Bal Pharma reported Q1 FY27 revenue of Rs 89 crore, up 33.7% year on year, and PAT of Rs 1.14 crore, up 442.9% year on year.

Is Bal Pharma a good buy after its Q1 FY27 results?

Ans. Bal Pharma's core numbers improved this quarter, though at a PE of 20.9x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.

What is the Bal Pharma share price today?

Ans. The Bal Pharma share price was trading around Rs 114 in late August 2026, about 0.0% below its 52-week high of Rs 114 and well above its 52-week low of Rs 60.

What is Bal Pharma's revenue and profit for Q1 FY27?

Ans. Bal Pharma reported revenue of Rs 89 crore and a net profit of Rs 1.14 crore for the quarter ended June 30, 2026.

Did Bal Pharma declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Bal Pharma's Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

What is Bal Pharma's PE ratio and is it expensive?

Ans. The Bal Pharma share price trades at a trailing PE of 20.9x, against an industry average of 38.0x. Investors should compare this with the company's growth rate before judging value.

What are the key risks for Bal Pharma investors right now?

Ans. A debt-to-equity ratio of 1.94 means the company's earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Bal Pharma's promoter shareholding?

Ans. Promoter shareholding data for Bal Pharma was not fully available for this quarter and should be checked on the company's official filings.